Related Experiment Video
Updated: Jul 3, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Tirapazamine: from bench to clinical trials
1Royal Adelaide Hospital, Department of Medical Physics, University of Adelaide, School of Chemistry and Physics, Adelaide, Australia. lmarcu@mail.rah.sa.gov.au
Current Clinical Pharmacology
|August 1, 2008
Summary
Tirapazamine shows promise in enhancing cancer treatments like chemotherapy and radiotherapy, particularly when combined with cisplatin. Further clinical studies are needed to fully understand its effects and toxicity in treating solid tumours.
Area of Science:
- Oncology
- Pharmacology
- Radiotherapy
Background:
- Tumour hypoxia presents a significant challenge in solid tumour treatment.
- Hypoxic cytotoxins, such as tirapazamine, are being investigated to overcome this challenge.
- Tirapazamine is a bioreductive agent designed to target hypoxic tumour cells.
Purpose of the Study:
- To review the history, biochemistry, and pharmacokinetics of tirapazamine.
- To evaluate the synergistic effects of tirapazamine with radiotherapy and chemotherapy, specifically cisplatin.
- To summarize findings from preclinical models and clinical trials involving tirapazamine.
Main Methods:
- Literature review of preclinical studies and clinical trials.
- Analysis of biochemical and pharmacokinetic data for tirapazamine.
- Examination of data on combined treatment effects (tirapazamine with radiation and cisplatin).
Main Results:
- Tirapazamine demonstrates enhanced anti-tumour effects when combined with radiation and cisplatin.
- Considerable evidence supports tirapazamine's potentiation of cisplatin's anti-tumour activity.
- Multiple clinical trials have investigated the cisplatin-tirapazamine combination with and without radiotherapy.
Conclusions:
- Tirapazamine shows potential as an adjunct therapy for solid tumours, particularly with cisplatin.
- Further research is warranted to address unanswered questions regarding tirapazamine's action and toxicity.
- Ongoing clinical studies are crucial for determining optimal administration and comprehensive conclusions.
More Related Videos
10:29The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 12, 2010
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...